Fabre-Kramer Products focus on the development of psychiatry and neurology. The pipeline consists of EXXUA™, FKO1MDD, FKBO1MD, FKWOOG, FKFO2SC, and FKFO1PD products majority of which are in advanced clinical development. The lead compound EXXUA™ expects approval in 2023.
As a virtual company, FKP forms partnerships with individual researchers, research institutions,
pharmaceutical as well as biotechnology companies, to license in molecules for development and further license them out for commercialization.
Fabre-Kramers expertise is concentrated around clinical development of compounds in the area of psychiatry and neurology.